Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
暂无分享，去创建一个
Melissa F. Adasme | Y. Moreau | M. Schroeder | V. J. Haupt | G. Jennings | Sebastian Salentin | B. Sprangers | J. Heinrich | D. Parisi | Jean Herman | T. Louat | Kristien Van Belle | Gary S. Jennings